Advances in Gastrointestinal and Liver Disease: From Physiological Mechanisms to Clinical Practice, 2nd Edition

Abstract submission deadline

25 July 2026

Manuscript submission deadline

20 December 2026

Viewed by

43

Topic Information

Dear Colleagues,

The management of gastrointestinal and hepatic diseases is constantly evolving. The progressive understanding of pathogenic mechanisms has improved daily management, representing real translational medicine. For example, understanding the mechanisms underlying HCV virus infection has enabled the development of Direct-Acting Antivirals (DAAs), with a cure rate of 98%. However, patients with advanced liver disease, albeit cured from HCV infection, are still at risk of hepatocellular carcinoma (HCC) development. Therefore, these patients will remain a medical challenge for years to come. New antiviral agents are currently under development for the treatment of chronic delta hepatitis (CHD).

Hopefully, in the near future we will be able to at least control liver disease progression in patients with CHD, the most severe form of chronic viral hepatitis. In the coming decades, NAFLD/NASH will supplant viral hepatitis as the leading cause of chronic liver damage. Efforts are ongoing to identify novel biomarkers and tools for the detection of liver fibrosis and stratify the risk of liver disease progression. Moreover, novel molecules targeting several pathways involved in NAFLD onset and progression are under investigation. The decrease in the prevalence of Helicobacter pylori (H. pylori) infection, the widespread use of proton pump inhibitors, and the relative ease of access to gastroscopies have reduced the incidence of peptic disease and stomach cancer, which was once the main gastrointestinal pathology. In many areas of the world, however, H. pylori infection remains widespread, and there is still room for improvement in eradication strategies. Understanding the inflammatory pathways involved in inflammatory bowel disease has enabled the development of target therapies (anti-TNF, anti-IL12/23, anti-JAK, S1P1 modulators). Increased understanding of the microbiome will lead to applications that will go beyond the confines of the gut, although the COVID-19 pandemic will continue to affect the management of all diseases.

The objective of this Topic is to present the most up-to-date data on the pathogenesis and management of gastrointestinal and hepatological diseases, with a view to an increasingly personalized management of patients.

Dr. Davide Giuseppe Ribaldone
Dr. Gian Paolo Caviglia
Topic Editors

Keywords

Participating Journals

Journal Name	Impact Factor	CiteScore	Launched Year	First Decision (median)	APC
Biomedicines biomedicines	3.9	6.8	2013	17 Days	CHF 2600	Submit
Current Oncology curroncol	3.4	4.9	1994	21.5 Days	CHF 2200	Submit
Diagnostics diagnostics	3.3	5.9	2011	21 Days	CHF 2600	Submit
Journal of Clinical Medicine jcm	2.9	5.2	2012	17.7 Days	CHF 2600	Submit
Livers livers	2.4	3.2	2021	27.8 Days	CHF 1200	Submit
Transplantology transplantology	-	1.4	2020	38.9 Days	CHF 1000	Submit
Gastrointestinal Disorders gastrointestdisord	0.8	1.2	2019	19.2 Days	CHF 1400	Submit

Preprints.org is a multidisciplinary platform offering a preprint service designed to facilitate the early sharing of your research. It supports and empowers your research journey from the very beginning.

MDPI Topics is collaborating with Preprints.org and has established a direct connection between MDPI journals and the platform. Authors are encouraged to take advantage of this opportunity by posting their preprints at Preprints.org prior to publication:

1. Share your research immediately: disseminate your ideas prior to publication and establish priority for your work.
2. Safeguard your intellectual contribution: Protect your ideas with a time-stamped preprint that serves as proof of your research timeline.
3. Boost visibility and impact: Increase the reach and influence of your research by making it accessible to a global audience.
4. Gain early feedback: Receive valuable input and insights from peers before submitting to a journal.
5. Ensure broad indexing: Web of Science (Preprint Citation Index), Google Scholar, Crossref, SHARE, PrePubMed, Scilit and Europe PMC.

Related Topic

Published Papers